Adcetris
(Brentuximab vedotin)Phase 3Antibody–drug conjugate
PfizerBrentuximab vedotin is used to treat certain types of lymphomas (blood cancers) and a skin cancer called cutaneous T-cell lymphoma. It works by targeting cancer cells and delivering chemotherapy directly to them.[1] Adcetris is currently being investigated across 31 indications[3], with its most advanced program in Phase 3.[1]
Adcetris is one of 514 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
31
Indications
164
Total Trials
49
Active Trials
513
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 31 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Adcetris
PfizerPhase 3
Velban
EEastern Cooperative Oncology Group
Preclinical
Oncaspar
SServier
Preclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma87 trials
Show 84 more trials
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
Withdrawn·—·Phase 1·NCT03373305
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Not yet recruiting·—·Phase 2·NCT07275216·23 enrolled
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 1/2·NCT02243436·67 enrolled
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT03057795·62 enrolled
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Unknown status·—·Phase 2·NCT06201507·44 enrolled
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01900496·6 enrolled
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03517137·150 enrolled
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT03233347·82 enrolled
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Active, not recruiting·—·Phase 2·NCT03113500·48 enrolled
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT02758717·46 enrolled
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
Completed·—·Phase 2·NCT01393717·57 enrolled
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Completed·—·Phase 2·NCT02744612·39 enrolled
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
Enrolling by invitation·NN.N. Petrov National Medical Research Center of Oncology·Phase 3·NCT07258680·114 enrolled
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
Completed·—·Phase 1/2·NCT01994850·32 enrolled
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Completed·—·Phase 1·NCT03013933·29 enrolled
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Recruiting·—·Phase 2·NCT04561206·31 enrolled
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy
Unknown status·KKing Abdullah International Medical Research Center·Phase 2·NCT03527628·220 enrolled
Brentuximab Vedotin15 trials
Show 12 more trials
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT05149768·11 enrolled
Anaplastic Large Cell Lymphoma8 trials
Show 5 more trials
Diffuse Large B-Cell Lymphoma6 trials
Show 3 more trials
Mycosis Fungoides5 trials
27 more indications
Classic Hodgkin Lymphoma4 trials
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT03712202·155 enrolled
Cutaneous T-cell lymphoma4 trials
Germ Cell Tumor3 trials
Relapsed/Refractory3 trials
Hodgkin Lymphoma3 trials
Systemic Sclerosis2 trials
Brentuximab Vedotin for Systemic Sclerosis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03222492·17 enrolled
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT03198689·11 enrolled
Relapsed or Refractory2 trials
Leukemia2 trials
Recurrent Classic Hodgkin Lymphoma2 trials
Treatment1 trial
Hematologic Malignancies1 trial
Systemic Mastocytosis1 trial
Allogeneic Stem Cell Transplantation1 trial
Malignant Mesothelioma1 trial
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Melanoma1 trial
Stage III1 trial
Recurrent Follicular Lymphoma1 trial
Ann Arbor Stage IIB Hodgkin Lymphoma1 trial
Regulatory
FDA Approval Timeline[4]
Aug 19, 2011
ADCETRIS
BLA BLA125388
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brentuximab vedotin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]